Theriva Biologics (NYSEAMERICAN:TOVX) Upgraded at Maxim Group

Maxim Group upgraded shares of Theriva Biologics (NYSEAMERICAN:TOVX) from a hold rating to a buy rating in a research report report published on Tuesday, MarketBeat Ratings reports. Maxim Group currently has $1.00 price objective on the stock.

Theriva Biologics Trading Up 1.5%

Shares of Theriva Biologics stock opened at $0.23 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.74 and a quick ratio of 1.74. Theriva Biologics has a 1 year low of $0.16 and a 1 year high of $1.50. The firm has a market cap of $7.76 million, a PE ratio of -0.01 and a beta of 0.47. The company has a 50 day simple moving average of $0.19 and a two-hundred day simple moving average of $0.26.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its quarterly earnings results on Thursday, March 12th. The company reported $1.30 EPS for the quarter.

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP purchased a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned approximately 0.64% of Theriva Biologics as of its most recent SEC filing. 6.17% of the stock is owned by hedge funds and other institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.